CSIR-Indian Institute of Integrative Medicine (CSIR-IIIM)
Dr. Prasad Kancherla currently serves as a Senior Scientist at the CSIR-Indian Institute of Integrative Medicine, where responsibilities include identifying new product and molecule opportunities across various dosage forms and analyzing market sales, competition, patent expiries, and technical complexities. Prior to this role, Dr. Kancherla held the position of Assistant Manager in Intellectual Property Rights at Aurobindo Pharma, focusing on launch analysis of generic drug markets and identifying Para IV product opportunities. Additionally, experience as a Senior Knowledge Scientist at SciTech Patent Art Services involved conducting patentability assessments and competitive intelligence. Dr. Kancherla holds a PhD in Chemistry from Jawaharlal Nehru Technological University and is currently pursuing a Professional Certificate Program in Advanced Business Management from the Indian Institute of Management, Kozhikode.
This person is not in any teams
This person is not in any offices
CSIR-Indian Institute of Integrative Medicine (CSIR-IIIM)
Indian Institute of Integrative Medicine (IIIM) is a national Institute of the Council of Scientific & Industrial Research (CSIR) of India. The mandate of IIIM is to be an internationally competitive centre of excellence in all facets of natural products research and technology, including (a) discovery of novel pharmacologically active natural products from plants and microbial species and translating them into drug leads and candidates by medicinal chemistry, preclinical pharmacology and clinical development. This approach is pursued both in NCE as well as botanical herbal mode; (b) Preclinical and clinical validation and establishment of mechanism of action of drugs used in various Indian systems of Medicines (Ayurveda, Unani, Siddha and other Indigenous systems of medicine); (c) develop agro-technologies and commercial cultivation of high value medicinal and aromatic plants from Western Himalayas including Kashmir Valley and Laddkh for national and international markets; and (d) to work with Indian and global pharmaceutical industry to out-license new products and technologies.